Multidrug-Resistant Tuberculosis Treatment in North Korea: Is Scale-Up Possible?

PLoS Med. 2016 Aug 2;13(8):e1002062. doi: 10.1371/journal.pmed.1002062. eCollection 2016 Aug.

Authors

Kwonjune J Seung^{1

2

3

4}, Molly Franke^{2

4}, Stephen W Linton¹

Affiliations

¹ Eugene Bell Foundation, New Freedom, Pennsylvania, United States of America.
² Partners In Health, Boston, Massachusetts, United States of America.
³ Brigham and Women's Hospital, Division of Global Health Equity, Boston, Massachusetts, United States of America.
⁴ Harvard Medical School, Boston, Massachusetts, United States of America.

Abstract

Kwonjune Seung and colleagues describe the Eugene Bell Foundation's experience of treating MDR-TB in North Korea.

MeSH terms

Adult
Antitubercular Agents / administration & dosage
Antitubercular Agents / therapeutic use*
Capacity Building*
Democratic People's Republic of Korea / epidemiology
Female
Humans
Male
Middle Aged
Treatment Outcome
Tuberculosis, Multidrug-Resistant / diagnosis
Tuberculosis, Multidrug-Resistant / drug therapy*
Tuberculosis, Multidrug-Resistant / epidemiology

Substances

Antitubercular Agents

Grants and funding

No specific funding was received for this study.